Hepatitis C in Children and Adolescents of a Brazilian Tertiary Center Identifying Patients Eligible for Direct-Acting Antivirals

Imagem de Miniatura
Arquivos
art_HIRSCH_Hepatitis_C_in_Children_and_Adolescents_of_a_2020.PDF (250.26 KB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2020
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
Citação
PEDIATRIC INFECTIOUS DISEASE JOURNAL, v.39, n.9, p.E276-E278, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
We evaluated 113 pediatric patients with chronic hepatitis C from 2009 to 2019 at a Brazilian tertiary center. Seventy patients received pegylated-interferon treatment. The sustained virologic response was 61.4%, and 92.8% reported side effects. Currently, we are following 39 patients with chronic hepatitis C, 24 of whom are eligible for treatment with direct-acting antivirals according to Brazilian recommendations.
Palavras-chave
Hepatitis C, childre, peg-interferon, ribavirin, direct-acting antivirals
URI
https://observatorio.fm.usp.br/handle/OPI/38020
Referências
  1. [Anonymous], 2019, PROT CLIN DIR TER HE
  2. Benova L, 2014, CLIN INFECT DIS, V59, P765, DOI 10.1093/cid/ciu447
  3. Bortolotti F, 2008, GASTROENTEROLOGY, V134, P1900, DOI 10.1053/j.gastro.2008.02.082
  4. Druyts E, 2013, CLIN INFECT DIS, V56, P961, DOI 10.1093/cid/cis1031
  5. European Assoc Study Liver, 2018, J HEPATOL, V69, P461, DOI 10.1016/j.jhep.2018.03.026
  6. Indolfi G, 2018, LANCET CHILD ADOLESC, V2, P298, DOI 10.1016/S2352-4642(18)30037-3
  7. Indolfi G, 2018, J PEDIATR GASTR NUTR, V66, P505, DOI 10.1097/MPG.0000000000001872
  8. Modin L, 2019, J HEPATOL, V70, P371, DOI 10.1016/j.jhep.2018.11.013
  9. Nguyen J, 2019, J PEDIATR-US, V207, P90, DOI 10.1016/j.jpeds.2018.12.012
  10. Rosenthal P, 2020, HEPATOLOGY, V71, P31, DOI 10.1002/hep.30821

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - ODS/03